Offerpad Solutions Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Offerpad Solutions Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.81M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $918.82M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.31B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $3.95B | Feb 25, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.81M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $918.82M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.31B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $3.95B | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $867.54M | Mar 7, 2022 |
| FY2021 | Sep 30, 2021 | $540.29M | Mar 7, 2022 |
| FY2021 | Jun 30, 2021 | $378.65M | Mar 7, 2022 |
| FY2021 | Mar 31, 2021 | $283.97M | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | $223.23M | Mar 7, 2022 |
| FY2021 | Sep 30, 2020 | $186.37M | Mar 7, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.04M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $72.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $70.18M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $182.42M | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $70.29M | Mar 7, 2022 |
| FY2021 | Sep 30, 2021 | $53.12M | Mar 7, 2022 |
| FY2021 | Jun 30, 2021 | $50.86M | Mar 7, 2022 |
| FY2021 | Mar 31, 2021 | $33.54M | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | $25.26M | Mar 7, 2022 |
| FY2021 | Sep 30, 2020 | $19.77M | Mar 7, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($46.38M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($62.16M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($117.22M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($148.61M) | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $12.81M | Mar 7, 2022 |
| FY2021 | Sep 30, 2021 | ($15.30M) | Mar 7, 2022 |
| FY2021 | Jun 30, 2021 | $9.19M | Mar 7, 2022 |
| FY2021 | Mar 31, 2021 | ($233.0K) | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | ($1.32M) | Mar 7, 2022 |
| FY2020 | Sep 30, 2020 | $0 | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.39M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($46.04M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($104.41M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($127.32M) | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $3.34M | Mar 7, 2022 |
| FY2021 | Sep 30, 2021 | $3.46M | Mar 7, 2022 |
| FY2021 | Jun 30, 2021 | $11.53M | Mar 7, 2022 |
| FY2021 | Mar 31, 2021 | $1.44M | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | $424.0K | Mar 7, 2022 |
| FY2021 | Sep 30, 2020 | ($1.92M) | Mar 7, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.41M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.52M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.95M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $12.09M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $10.86M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $7.27M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $7.45M | Mar 7, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.81M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $20.83M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $261.63M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $305.40M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($921.92M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($491.7K) | May 25, 2021 |
| FY2021 | Dec 31, 2019 | ($108.97M) | Mar 7, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $5.41M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $127.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.07M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $13.69M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $2.86M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.04M | Mar 7, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.77M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $313.05M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $379.69M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $825.07M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.35B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $235.87M | Mar 7, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.55M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $265.40M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $277.92M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $703.19M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.10B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $195.01M | Mar 7, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.22M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $47.65M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $101.78M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $121.88M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $257.57M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | ($143.26M) | Feb 27, 2024 |
| FY2020 | Sep 30, 2020 | $25.0K | Mar 31, 2021 |
| FY2020 | Aug 31, 2020 | $0 | Mar 31, 2021 |
| FY2020 | Aug 30, 2020 | $0 | May 25, 2021 |
| FY2022 | Dec 31, 2019 | ($121.50M) | Feb 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($506.43M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($460.05M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($397.89M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($280.67M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($132.06M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($138.52M) | Mar 7, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.54M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $43.02M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $75.97M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $97.24M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $169.82M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $43.94M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $22.86M | Mar 7, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (9) | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 7, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (9) | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 7, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 7, 2022 |